Literature DB >> 29169572

Opportunistic salpingectomy in women undergoing hysterectomy: Results from the HYSTUB randomised controlled trial.

L A M Van Lieshout1, B Pijlman2, M C Vos3, M J M de Groot4, S Houterman5, S F P J Coppus6, M G Harmsen7, I Vandenput8, J M J Piek9.   

Abstract

OBJECTIVE: To evaluate whether opportunistic salpingectomy in premenopausal women undergoing hysterectomy for benign indications is both hormonally and surgically safe, compared with hysterectomy without salpingectomy. STUDY
DESIGN: In this multicentre randomised controlled trial, women were randomised to undergo either hysterectomy with opportunistic bilateral salpingectomy (intervention group) or standard hysterectomy with preservation of the Fallopian tubes (control group). MAIN OUTCOME MEASURES: The primary outcome was the difference in serum anti-Müllerian hormone concentration (ΔAMH), measured pre-surgery and 6 months post-surgery. Secondary outcomes were surgical outcomes and duration of hospital stay. The sample size was powered at 50 participants per group (n=100) to compare ΔAMH after hysterectomy with salpingectomy to ΔAMH after standard hysterectomy.
RESULTS: Between March 2013 and December 2016, 104 women, aged 30-55 years, were randomly allocated to hysterectomy with opportunistic bilateral salpingectomy (n=52) or standard hysterectomy (n=52). The baseline characteristics did not differ between the two groups. The median ΔAMH was -0.14pmol/L (IQR -1.47-0.95) in the intervention group and 0.00pmol/L (IQR -1.05-0.80) in the control group (p=0.49). The addition of salpingectomy did not impair surgical results and it did not affect duration of hospital stay.
CONCLUSION: Addition of opportunistic bilateral salpingectomy during hysterectomy did not result in a larger effect on ovarian reserve when compared with hysterectomy alone, neither did it affect surgical outcomes. Therefore, opportunistic salpingectomy seems to be a safe procedure in premenopausal women undergoing hysterectomy for benign gynaecological conditions.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-Müllerian hormone; High-Grade serous ovarian carcinoma; Opportunistic salpingectomy; Ovarian reserve; Prevention

Mesh:

Substances:

Year:  2017        PMID: 29169572     DOI: 10.1016/j.maturitas.2017.09.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  6 in total

1.  Re: The Association Between Hysterectomy and Ovarian Cancer Risk: A Population-Based Record-Linkage Study.

Authors:  Paul J van Diest; Ronald P Zweemer; Jurgen M J Piek
Journal:  J Natl Cancer Inst       Date:  2019-12-01       Impact factor: 13.506

2.  Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.

Authors:  Laura A M van Lieshout; Miranda P Steenbeek; Joanne A De Hullu; M Caroline Vos; Saskia Houterman; Jack Wilkinson; Jurgen Mj Piek
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

3.  Bilateral salpingectomy versus bilateral partial salpingectomy during cesarean delivery.

Authors:  Jose R Duncan; Heather L Jones; Stefanie O Hoffer; Mauro H Schenone; Giancarlo Mari
Journal:  Int J Womens Health       Date:  2018-10-23

4.  Factors influencing decision-making around opportunistic salpingectomy: a nationwide survey.

Authors:  Miranda P Steenbeek; Laura A M van Lieshout; Johanna W M Aarts; Jurgen M J Piek; Sjors F P J Coppus; Leon F A G Massuger; Rosella P M G Hermens; Joanne A de Hullu
Journal:  J Gynecol Oncol       Date:  2018-04-30       Impact factor: 4.401

5.  Survey: acceptability of opportunistic bilateral salpingectomy in Flanders.

Authors:  A S Maryns; A Makar; T Hamerlynck; B De Vree; P Tummers; W A A Tjalma
Journal:  Facts Views Vis Obgyn       Date:  2021-09

Review 6.  Bilateral salpingectomy to reduce the risk of ovarian/fallopian/peritoneal cancer in women at average risk: a position statement of the Korean Society of Obstetrics and Gynecology (KSOG).

Authors:  Miseon Kim; Young-Han Kim; Yong Beom Kim; Jayeon Kim; Jae-Weon Kim; Mi Hye Park; Joo Hyun Park; Jeong Ho Rhee; Myong Cheol Lim; Joon-Seok Hong
Journal:  Obstet Gynecol Sci       Date:  2018-09-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.